ArticleJournal of advanced research2026
Boosting luteolin bioavailability via P-glycoprotein efflux inhibition: a self-microemulsifying drug delivery systems.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-Target Modulation of Interconnected Pathogenetic Pathways by Natural Bioactive Compounds in Endometriosis.Antioxidants (Basel, Switzerland) · 2026Review
- Role of Plant-Derived Antioxidants in Oxidative Stress-Associated Myocardial Infarction: Structure-Activity Relationship (SAR)-Based Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe poor bioavailability of luteolin, a potent flavonoid with antioxidant and anti-inflammatory properties, hinders its therapeutic potential. The primary barriers to its absorption are its low solubility and active efflux by P-glycoprotein (P-gp) in the gastrointestinal tract.
objectivesTo overcome these absorption barriers, we developed a functional self-microemulsifying drug delivery system (SME) incorporating D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), aiming to simultaneously enhance solubility, inhibit P-gp efflux, and improve the oral bioavailability and therapeutic efficacy of luteolin.
methodsA TPGS-based luteolin-SME was prepared via self-assembly and characterized for particle size, stability, release profile, and antioxidant capacity. Cellular absorption mechanisms, permeability, and P-gp inhibition were evaluated using Caco-2 monolayers and molecular docking. Pharmacokinetics and biodistribution were assessed in rats, and therapeutic efficacy was examined in a lipopolysaccharide-induced inflammation model.
resultsThe optimized luteolin-SME formed uniform nanodroplets (<50 nm) with high stability and achieved a 4.3-fold higher cumulative release compared to free luteolin. In Caco-2 cells, the formulation significantly enhanced cellular uptake and permeability, primarily via clathrin- and caveolae-mediated endocytosis, and effectively inhibited P-gp efflux. Pharmacokinetically, luteolin-SME provided a 29-fold increase in relative bioavailability (AUC 247.729 vs. 8.628 mg/L·h) and a 16-fold higher Cmax (27.546 mg/L) over free luteolin. In the lipopolysaccharide-induced inflammation model, luteolin-SME markedly attenuated oxidative stress, reducing the TNF-α, IL-6, and IL-1β levels by approximately 37%, 26%, and 39%, respectively.
conclusionThe TPGS-functionalized SME effectively overcame the major absorption barriers of luteolin by integrating nanocarrier-enhanced solubilization with active P-gp inhibition. This dual strategy resulted in unprecedented oral bioavailability enhancement and potent efficacy. Our study establishes a robust and clinically promising delivery platform for luteolin and other poorly soluble, efflux-limited bioactive compounds, offering a practical approach to enhance oral therapy for inflammation-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.